Table 2. MBL expression type and characteristics of all study patients.
| Total | deficient | low | high+int | p | |
|---|---|---|---|---|---|
| (n = 632) | (n = 12) | (n = 33) | (n = 587) | ||
| 100.0% | 1.9% | 5.2% | 92.9% | 0.409 | |
| Male sex | 265 (41.9%) | 7(58.3%) | 1 (33.3%) | 247(42,1%) | 0.311 |
| Age (range) | 33 (15–63) | 33(28–47) | 33 (18–60) | 33(15–63) | 0.732 |
| CD4+ cell count/μl | 154 | 241 | 90 | 156 | 0.518 |
| (range) | (0–1191) | (10–412) | (0–762) | (0–1191) | |
| log10VL (copies/ml) | 5.19 | 4.63 | 5.23 | 5.19 | 0.858 |
| (range) | (2.60–6.72) | (2.60–6.28) | (2.60–6.07) | (2.60–6.72) | |
| PCP | 96 (15.2%) | 5(41.7%) | 10 (30.3%) | 81(13.8%) | 0.001† |
| Cryptococcosis | 83 (13.2%) | 1(8.3%) | 6 (18.2%) | 76(13.0%) | 0.609 |
| Talaromycosis | 49 (7.8%) | 0(0.0%) | 2 (4.1%) | 47(8.0%) | 0.550 |
| Toxoplasmosis | 30 (4.8%) | 1(8.3%) | 3 (9.1%) | 26(4.5%) | 0.4.4 |
| Tuberculosis | 118 (18.7%) | 3(25.0%) | 5 (15.2%) | 110(18.8%) | 0.745 |
| HBsAg | 70(11.2%) | 3(25.0%) | 4(12.1%) | 63(10.9%) | 0.304 |
| HCVAb | 24(3.8%) | 1(8.3%) | 0(0.0%) | 23(4.0%) | 0.368 |
Abbreviations: high+int, high and intermediate; VL, HIV-RNA viral load; PCP, Pneumocystis jirovecii pneumonia. Kruskal-Wallis test was used to compare the medians of continuous variables, and the chi-square test was used to compare categorical variables.
†statistically significant (p<0.05).